The Sequence Listing

𝗛𝗼𝘄 𝗠𝘂𝗰𝗵 𝗗𝗼𝗲𝘀 𝗦𝗲𝗾𝘂𝗲𝗻𝗰𝗲 𝗟𝗶𝘀𝘁𝗶𝗻𝗴 𝗣𝗿𝗲𝗽𝗮𝗿𝗮𝘁𝗶𝗼𝗻 𝗖𝗼𝘀𝘁? 𝗔 𝗣𝗿𝗮𝗰𝘁𝗶𝗰𝗮𝗹 𝗣𝗿𝗶𝗰𝗶𝗻𝗴 𝗚𝘂𝗶𝗱𝗲 🧬 When a patent application includes nucleotide or amino acid sequences, a compliant sequence listing isn’t optional - it’s a global filing requirement under the ST.26 standard. What often surprises applicants is just how much the cost can vary depending on sequence count, complexity and data quality. 🔑 𝗪𝗵𝗮𝘁 𝗗𝗿𝗶𝘃𝗲𝘀 𝗦𝗲𝗾𝘂𝗲𝗻𝗰𝗲 𝗟𝗶𝘀𝘁𝗶𝗻𝗴 𝗖𝗼𝘀𝘁𝘀: • Number of sequences (the primary cost driver) • Complexity of biologics (antibodies, gene constructs, CRISPR, etc.) • Quality of source data (FASTA vs. extracted drafts) • Annotation and ST.26 compliance requirements • Rush timelines or ST.25-to-ST.26 conversions 💰 𝗧𝘆𝗽𝗶𝗰𝗮𝗹 𝗣𝗿𝗶𝗰𝗶𝗻𝗴 𝗥𝗮𝗻𝗴𝗲𝘀: • Small filings (1–10 sequences): ~$150–$1,200 depending on provider type • Mid-size filings (50–150 sequences): ~$1,000–$8,000 • Large genomic datasets (500+ sequences): $10,000 to $40,000+ • High-volume genomics projects: can exceed $50,000+ 💡 𝗞𝗲𝘆 𝗧𝗮𝗸𝗲𝗮𝘄𝗮𝘆: Sequence listing preparation has evolved from simple formatting into a specialized bioinformatics compliance task. The real cost isn’t just the number of sequences - it’s the complexity behind ensuring ST.26 accuracy, validation and patent office compliance across jurisdictions 𝗥𝗲𝗮𝗱 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝗮𝗿𝘁𝗶𝗰𝗹𝗲 𝗵𝗲𝗿𝗲: https://lnkd.in/gFYChQmf Get in Touch: info@thesequencelisting.com #SequenceListing   #PatentApplications   #BiotechPatents   #ST26   #WIPO   #USPTO   #IntellectualProperty   #IPLaw   #PatentStrategy   #Biotechnology

🚀 𝗦𝗲𝗾𝘂𝗲𝗻𝗰𝗲 𝗟𝗶𝘀𝘁𝗶𝗻𝗴𝘀 𝗶𝗻 𝗖𝗼𝗻𝘁𝗶𝗻𝘂𝗮𝘁𝗶𝗼𝗻𝘀 & 𝗗𝗶𝘃𝗶𝘀𝗶𝗼𝗻𝗮𝗹𝘀: 𝗔𝘃𝗼𝗶𝗱 𝗖𝗼𝘀𝘁𝗹𝘆 𝗖𝗼𝗺𝗽𝗹𝗶𝗮𝗻𝗰𝗲 𝗣𝗶𝘁𝗳𝗮𝗹𝗹𝘀! Navigating continuation and divisional patent applications with biological sequences? Get ST.26 XML rules right or face delays, office actions, and rejections. Our latest guide breaks down essentials for biotech innovators, patent agents, and IP pros. 𝗞𝗲𝘆 𝗜𝗻𝘀𝗶𝗴𝗵𝘁𝘀: • Incorporate parent's listing by reference only if no new sequences and proper spec language is used no new matter allowed. • Post-July 2022 filings demand ST.26 XML conversion from old ST.25 txt; use WIPO Sequence for validation. • Divisionals can carry full parent listing if relevant, but validate via Patent Center to catch errors early. • Top pitfalls: Missing "no new matter" statements, ID mismatches, unvalidated XML prevent with specialist review. 𝗠𝗮𝘀𝘁𝗲𝗿 𝘁𝗵𝗲𝘀𝗲 𝗳𝗼𝗿 𝘀𝘁𝗿𝗼𝗻𝗴𝗲𝗿 𝗽𝗮𝘁𝗲𝗻𝘁 𝗳𝗮𝗺𝗶𝗹𝗶𝗲𝘀. 𝗥𝗲𝗮𝗱 𝗳𝘂𝗹𝗹 𝗮𝗿𝘁𝗶𝗰𝗹𝗲: https://lnkd.in/gehydEF8 #SequenceListing #PatentApplications #BiotechPatents #ST26 #WIPO #USPTO #IntellectualProperty #IPLaw #PatentStrategy #Biotechnology

🔬 𝗠𝗮𝘀𝘁𝗲𝗿𝗶𝗻𝗴 𝗔𝗺𝗶𝗻𝗼 𝗔𝗰𝗶𝗱 𝗦𝗲𝗾𝘂𝗲𝗻𝗰𝗲 𝗩𝗮𝗿𝗶𝗮𝗻𝘁 𝗗𝗶𝘀𝗰𝗹𝗼𝘀𝘂𝗿𝗲 𝗶𝗻 𝗣𝗮𝘁𝗲𝗻𝘁𝘀 🧬 Protecting protein-based therapeutics starts with proper patent disclosure. A single amino acid change can make or break your IP strategy - and courts are scrutinizing disclosures more closely than ever. Our latest article, “Amino Acid Sequence Variants: Proper Patent Disclosure Methods”, is a must-read for patent practitioners, biotech researchers, and IP professionals. Here’s what you’ll learn: ✅ Why complete disclosure is critical for robust patent rights in biologics ✅ Key elements of proper amino acid variant disclosure:   • Full sequence listings (one-letter/three-letter code)   • Position-specific modifications & wild-type residues   • Functional data & structural context ✅ Sequence listing compliance with WIPO ST.25/ST.26 formats ✅ Disclosure strategies for:   • Conservative substitutions   • Non-conservative & functional variants   • Variant libraries (consensus, combinatorial, enumerated) ✅ Common pitfalls to avoid (insufficient examples, overly broad claims, technical errors) ✅ Jurisdictional nuances: USPTO, EPO, JPO, and China requirements ✅ Best practices for future-proof patent protection 📌 𝗣𝗿𝗼 𝘁𝗶𝗽: Disclose broadly, claim strategically, and document everything — your future IP portfolio will thank you. 🔗 𝗥𝗲𝗮𝗱 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝗴𝘂𝗶𝗱𝗲 𝗵𝗲𝗿𝗲: https://lnkd.in/gjSc_jGq #PatentStrategy #BiotechIP #AminoAcids #SequenceListing #PatentDisclosure #IntellectualProperty #Biopharma #PatentDrafting #WIPO #USPTO #EPO #JPO #ProteinTherapeutics #IPProtection #PatentAttorney #R&D #Innovation #Biotechnology #PatentLaw #SequenceVariants

✨🌙 Effectual Services wishes everyone a blessed and peaceful Eid al-Adha Mubarak! Eid al-Adha reminds us of the values of sacrifice, dedication, gratitude and compassion. As a company, we draw inspiration from these principles by strengthening teamwork, building trust, supporting one another and staying committed to excellence with integrity and purpose. 🤝✨ May this auspicious occasion bring harmony, success, prosperity and happiness to you and your families. 🌟🤍 #EidAlAdha #EidMubarak #EffectualServices #CorporateValues #Teamwork #Leadership #Integrity #Growth #Inclusivity #Compassion #FestivalOfSacrifice #TogetherWeGrow #HappyEid

🧬 𝗦𝗧.𝟮𝟲 𝘃𝘀 𝗦𝗧.𝟮𝟱: 𝗪𝗵𝗮𝘁 𝗘𝘃𝗲𝗿𝘆 𝗣𝗮𝘁𝗲𝗻𝘁 𝗙𝗶𝗹𝗲𝗿 𝗡𝗲𝗲𝗱𝘀 𝘁𝗼 𝗞𝗻𝗼𝘄 𝗶𝗻 𝟮𝟬𝟮𝟲 If you work in patent filing especially for biotech or pharmaceutical inventions you can no longer ignore the shift from ST.25 to ST.26. This isn’t just a format change; it’s a major evolution in how biological sequences are disclosed globally. ✅ 𝗞𝗲𝘆 𝗱𝗶𝗳𝗳𝗲𝗿𝗲𝗻𝗰𝗲𝘀 𝘆𝗼𝘂 𝗺𝘂𝘀𝘁 𝗸𝗻𝗼𝘄:   • File Format: ST.25 = plain text (.txt) | ST.26 = structured XML (.xml)   • Scope: ST.26 covers circular sequences, modified bases, D-amino acids, gaps & more   • Annotations: ST.26 uses standardized, searchable feature annotations (INSDC-controlled vocabulary)   • Tool Requirement: ST.26 mandates WIPO Sequence tool (no manual text files)   • Validation: Built-in validation reduces office actions & rejections   • Compliance Deadline: All new applications since July 1, 2022 must use ST.26 🔍 A well-formatted ST.26 listing improves claim clarity, examiner understanding, and future-proofs your IP against evolving databases and analytics tools. 📖 𝗗𝗶𝘃𝗲 𝗱𝗲𝗲𝗽𝗲𝗿 𝗶𝗻𝘁𝗼 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝗦𝗧.𝟮𝟲 𝘃𝘀 𝗦𝗧.𝟮𝟱 𝗰𝗼𝗺𝗽𝗮𝗿𝗶𝘀𝗼𝗻 𝗵𝗲𝗿𝗲: 👉 https://lnkd.in/gqWTRYui #PatentFiling #ST26 #ST25 #SequenceListing #WIPOSequence #BiotechPatents #PharmaIP #IntellectualProperty #PatentAttorney #Bioinformatics #PatentCompliance #IPStrategy #PatentDrafting #WIPONews #PatentExamination

𝗦𝗲𝗾𝘂𝗲𝗻𝗰𝗲 𝗟𝗶𝘀𝘁𝗶𝗻𝗴 𝗘𝘀𝘀𝗲𝗻𝘁𝗶𝗮𝗹𝘀 𝗳𝗼𝗿 𝗕𝗶𝗼𝘁𝗲𝗰𝗵 𝗦𝘁𝗮𝗿𝘁𝘂𝗽𝘀: 𝗗𝗼𝗻’𝘁 𝗟𝗲𝘁 𝗖𝗼𝗺𝗽𝗹𝗶𝗮𝗻𝗰𝗲 𝗗𝗲𝗿𝗮𝗶𝗹 𝗬𝗼𝘂𝗿 𝗜𝗣 If your biotech startup is built around a novel gene, protein, antibody, or nucleic acid, your patent success hinges on getting the sequence listing right from day one. 𝗜𝗻 𝘁𝗵𝗶𝘀 𝗽𝗼𝘀𝘁 𝘄𝗲 𝗯𝗿𝗲𝗮𝗸 𝗱𝗼𝘄𝗻:   • What a sequence listing is and why it’s mandatory when your DNA, RNA, or amino acid sequences are 10+ residues long.   • The global shift to WIPO Standard ST.26 (XML format) and why using old ST.25 text files is a fast track to rejection.   • The core requirements every listing must include: applicant details, organism names (including “Artificial Sequence”), feature tables, exact sequence data, and consistent SEQ IDs.   • Top mistakes early‑stage biotech companies make: inconsistent sequences, missing organism/feature annotations, and late filing.   • How to think strategically about sequence‑heavy patents: disclose sequence families, coordinate your science and IP teams, and plan for international (PCT/EPO/Asia) filings.   • When to bring in a sequence listing specialist and why this small investment can prevent costly office actions, rejections, and delays. For biotech startups, sequence listings aren’t just paperwork they’re core to how your IP is defined, disclosed, and enforced. 📚 𝗥𝗲𝗮𝗱 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝗴𝘂𝗶𝗱𝗲 𝗵𝗲𝗿𝗲: https://lnkd.in/gW6KCfxS #Biotech #BiotechStartups #LifeSciences #Patents #IPStrategy #SequenceListing #WIPOST26 #BiotechIP #Pharma #StartupIP #BiotechLaw #TechTransfer #WIPO #PatentFiling #EarlyStageStartup #BiotechInnovation

𝗦𝗲𝗾𝘂𝗲𝗻𝗰𝗲 𝗟𝗶𝘀𝘁𝗶𝗻𝗴𝘀 𝗶𝗻 𝗜𝗣𝗥: 𝗔 𝗖𝗿𝗶𝘁𝗶𝗰𝗮𝗹 𝗕𝗹𝗶𝗻𝗱 𝗦𝗽𝗼𝘁 𝗳𝗼𝗿 𝗕𝗶𝗼𝘁𝗲𝗰𝗵 & 𝗣𝗵𝗮𝗿𝗺𝗮 𝗣𝗮𝘁𝗲𝗻𝘁 𝗢𝘄𝗻𝗲𝗿𝘀 Inter Partes Review (IPR) is a powerful tool to challenge patents and in biotech/pharma, your sequence listing can make or break your defense. • In IPR, sequence listings shape claim interpretation and prior‑art comparisons at the PTAB. • Non‑compliance with WIPO ST.26, SEQ ID NO errors, or missing/inconsistent sequences create vulnerabilities. • Proactive audits, ST.26 compliance, and working with sequence‑listing experts can protect your IP before a petition arrives. 𝗥𝗲𝗮𝗱 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝗴𝘂𝗶𝗱𝗲: https://lnkd.in/gT69ZtDg #BiotechIP #PharmaPatents #SequenceListing #IPR #PTAB #WIPOST26 #PatentOwners #LifeSciencesIP #IntellectualProperty

🚀 𝗙𝗶𝗹𝗶𝗻𝗴 𝗕𝗶𝗼𝘁𝗲𝗰𝗵 𝗣𝗮𝘁𝗲𝗻𝘁𝘀 𝗶𝗻 𝗖𝗮𝗻𝗮𝗱𝗮? 𝗗𝗼𝗻’𝘁 𝗟𝗲𝘁 𝗦𝗲𝗾𝘂𝗲𝗻𝗰𝗲 𝗟𝗶𝘀𝘁𝗶𝗻𝗴 𝗘𝗿𝗿𝗼𝗿𝘀 𝗞𝗶𝗹𝗹 𝗬𝗼𝘂𝗿 𝗔𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻 If your invention involves DNA, RNA, or proteins, understanding CIPO’s sequence listing requirements isn’t optional it’s essential. One missed detail can delay your application, trigger objections, or even lead to rejection. ✅ 𝗞𝗲𝘆 𝗖𝗜𝗣𝗢 𝗦𝗲𝗾𝘂𝗲𝗻𝗰𝗲 𝗟𝗶𝘀𝘁𝗶𝗻𝗴 𝗥𝗲𝗾𝘂𝗶𝗿𝗲𝗺𝗲𝗻𝘁𝘀 𝗬𝗼𝘂 𝗠𝘂𝘀𝘁 𝗞𝗻𝗼𝘄:   • Mandatory for: Nucleotide sequences ≥10 bases or amino acid sequences ≥4 residues   • Format: ST.26 XML (WIPO SEQUENCE DTD) - ST.25 plain text is being phased out   • Language: English or French (matching your application)   • Unique IDs: Every sequence needs a consistent SEQ ID NO across claims & description   • Controlled Vocabulary: Only WIPO-approved organism names, feature keys, and qualifiers   • Submission: Separate electronic file (NOT embedded in the specification)   • Tool: Use free WIPO Sequence software to generate compliant XML files ⚠️ 𝗖𝗼𝗺𝗺𝗼𝗻 𝗠𝗶𝘀𝘁𝗮𝗸𝗲𝘀 𝗧𝗵𝗮𝘁 𝗚𝗲𝘁 𝗔𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻𝘀 𝗥𝗲𝗷𝗲𝗰𝘁𝗲𝗱:   • Submitting ST.25 when ST.26 is required (or vice versa)   • Inconsistent SEQ ID NO references between listing and claims   • Using informal/abbreviated organism names not in WIPO taxonomy   • Missing feature annotations (gene names, protein functions, etc.)   • Embedding sequence listing inside the patent PDF instead of as a standalone file 💡 𝗪𝗵𝘆 𝗧𝗵𝗶𝘀 𝗠𝗮𝘁𝘁𝗲𝗿𝘀: A non-compliant sequence listing isn’t just a technical glitch—it’s a legal & business risk. Applications can be deemed withdrawn, examination delayed by months/years, and competitors may beat you to patent grants in fast-moving biotech fields. 🔗 𝗙𝘂𝗹𝗹 𝗴𝘂𝗶𝗱𝗲: https://lnkd.in/gSeGRbJP 𝗣𝗿𝗼 𝗧𝗶𝗽: Work with an experienced Canadian patent agent who understands both the biology and legal compliance of sequence listings especially for PCT national phase entries! #BiotechPatents #IPStrategy #PatentFiling #CIPO #SequenceListing #ST26 #LifeSciences #PharmaIP #PatentAgent #CanadianPatents #BiotechInnovation #IPProtection #PatentCompliance #WIPOSequence #DrugDevelopment

𝗘𝘅𝗼𝘀𝗼𝗺𝗲 & 𝗘𝗩 𝗣𝗮𝘁𝗲𝗻𝘁𝘀: 𝗗𝗼𝗻’𝘁 𝗟𝗲𝘁 𝗬𝗼𝘂𝗿 𝗦𝗲𝗾𝘂𝗲𝗻𝗰𝗲 𝗟𝗶𝘀𝘁𝗶𝗻𝗴 𝗖𝗼𝘀𝘁 𝗬𝗼𝘂 𝗧𝗶𝗺𝗲 𝗮𝗻𝗱 𝗖𝗼𝘃𝗲𝗿𝗮𝗴𝗲 If you’re filing patents around exosomes or extracellular vesicles (EVs), your sequence listing can make or break the strength and speed of protection. In this in‑depth article, we unpack how exosome‑centric sequence listings differ from conventional biotech patents and why WIPO ST.26 compliance is now critical. 👉 𝗞𝗲𝘆 𝘁𝗮𝗸𝗲𝗮𝘄𝗮𝘆𝘀 𝘆𝗼𝘂 𝘀𝗵𝗼𝘂𝗹𝗱𝗻’𝘁 𝗺𝗶𝘀𝘀:   • Why exosome and EV patents often include multiple sequence types (miRNAs, siRNAs, mRNAs, aptamers, surface proteins, peptides) and why each affects your sequence listing.   • How ST.25 vs. ST.26 changes the game: mandatory XML format, separate DNA/RNA declarations, and strict annotation rules for modified nucleotides and amino acids.   • Why naturally occurring sequences inside exosomes still need formal listing if claimed or described in the context of your invention.   • Practical tips: how to run a full sequence audit, work with a specialist, validate your XML file, and keep claims and specification perfectly aligned. Getting your exosome patent sequence listing right isn’t just paperwork it’s a core part of your IP strategy in a fast‑growing, high‑value therapeutic space. 📄 𝗥𝗲𝗮𝗱 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝗮𝗿𝘁𝗶𝗰𝗹𝗲 𝗵𝗲𝗿𝗲: https://lnkd.in/gX7pjVae #ExosomeTherapeutics #ExtracellularVesicles #EVTherapeutics #BiotechPatents #GeneTherapy #RNATherapeutics #SequenceListing #WIPOST26 #PatentLaw #IPStrategy #BiopharmaInnovation #LifeSciencesIP